Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's ...

For context, Tempus uses AI to improve precision medicine solutions, as well as drug discovery and diagnostics. Its operating ...

Shares of Tempus AI (NASDAQ: TEM) are falling on Wednesday. One of Cathie Wood's largest holdings, the company's stock ...

An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward ...

在近期美股市场的动荡中，Tempus AI（股票代码：TEM.US）的股价遭遇了重创，周三收盘时下跌超过14%，报56.34美元。这一剧烈波动引发了市场的广泛关注，而背后的原因则是机构Spruce Point发布了一份针对该公司的做空报告。这份报告不仅对Tempus AI的管理层提出质疑，更揭示了其董事会成员的历史背景，令人不禁对公司的未来发展产生担忧。

凯西·伍德的ARK ETF公布了2025年5月28日周三的每日交易情况，揭示了该基金在科技和生物技术板块的一系列战略调整。当天最重要的交易是购入了251,080股Tempus AI Inc ...

Investing.com - Tempus AI (NASDAQ: TEM)股价在被Spruce Point做空报告点名后下跌4%。该报告对Tempus AI产品的完整性、管理层的可信度以及财务报告实践提出了严重质疑。 Spruce Point的报告基于对这家精准医疗解决方案公司的法务审查，批评Tempus ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its ...

U.S.-based Tempus AI came under intense pressure after a scathing short seller report raised red flags about the company’s valuation, business model, and financial transparency.

Spruce Point said Tempus’ revenue quality should be carefully scrutinized, because of signs of "aggressive accounting." ...

BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.